A new philanthropic fund called Intercept has launched with $500 million in seed funding from Anthropic, OpenAI Foundation, Stripe, and Bill Gates to tackle respiratory viruses — starting with the common cold and flu. The initiative will focus on developing broad-spectrum antivirals and air-cleaning technologies. Its ultimate goal: prevent pandemics by dramatically reducing the burden of everyday respiratory infections.
A new philanthropic organization called Intercept has launched with $500 million in seed funding from some of tech's biggest names — including Anthropic, the OpenAI Foundation, Stripe, Jane Street, and Bill Gates — with an ambitious mission: eliminate respiratory viruses, starting with the common cold and flu. The fund argues that while we treat these infections as minor annoyances, they kill 1 million people annually, cost $600 billion in lost productivity, and periodically spark civilization-threatening pandemics.
Intercept is betting on two main strategies: broad-spectrum preventatives (targeting rhinoviruses, influenza, coronaviruses, and more simultaneously) and air-cleaning technologies (like filtration, antimicrobial light, and antimicrobial vapors). The fund aims to advance at least two products to Phase 2 trials, after which it hopes pharma companies will take the baton.
By the Numbers:
Why it matters: This is one of the largest philanthropic bets on pandemic preparedness and everyday infectious disease prevention. If successful, it could reshape how the world approaches respiratory illness — from a recurring nuisance to a solvable public health problem.
